Out of the four inflection points indicated in the figure below, the Fund’s strategy will be to focus on two key junctures in the pharmaceutical development process highlighted in color namely and primarily: from Pre-clinical to Proof-of-Concept and secondarily on Proof-of-Concept to Phase III.

This strategy is based upon the following observations:

Large Pharmaceuticals

They constantly need new products to grow to meet financial expectations

Small Biotechs

They continue to be the main source of new ideas and innovations in the industry


Product company focused investments have proven historically to be attractive

Return on Investment

To consider an investment, there needs to be a favorable risk/reward profile ratio


    Source: Adapted with permission from JSB Partners